©2024 Stanford Medicine
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Not Recruiting
Trial ID: NCT03809078
Purpose
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for
biopsy guidance in patients with suspected prostate cancer.
Official Title
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Guido A. Davidzon
Clinical Associate Professor, Radiology - Rad/Nuclear Medicine
Geoffrey Sonn
Associate Professor of Urology and, by courtesy, of Radiology (Body MRI)
Farshad Moradi
Clinical Associate Professor, Radiology - Rad/Nuclear Medicine
Pejman Ghanouni, MD, PhD
Associate Professor of Radiology (General Radiology) and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology
Eligibility
Inclusion Criteria:
- Suspected prostate cancer
- Planned prostate biopsy
- Able to provide written consent
- Karnofsky performance status of 50 (or ECOG/WHO equivalent)
Exclusion Criteria:
- Patients not capable of getting PET study due to weight, claustrophobia, or inability
to lay still for the duration of the exam
- Metallic implants (contraindicated for MRI)
Intervention(s):
drug: 68Ga RM2
drug: 68Ga-PSMA-11
device: Investigational PET scanner coils and software
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Brittney Williams
650-736-3688